Trovagene is a molecular diagnostics company currently developing tests for screening, detection, and monitoring of cancer, organ transplantation, infectious disease, and prenatal genetic testing. The company has a claim to intellectual property based around the discovery that cell-free DNA, RNA, and other types of nucleic acids pass through the kidney into the urine. These "Transrenal Nucleic Acids" (TrNAs) can help diagnose certain diseases including cancer and infection.
Trovagene's non-invasive sampling and analysis of these nucleic acids can lead to early detection, effective treatment monitoring, and management of the illness. The company has both U.S. and European patents, as well as patent applications pending.
In September the company announced its agreement with Strand Life Sciences Pvt. Ltd., of Bangalore, India, to validate and commercialize Trovagene's proprietary urine-based Human Papillomavirus (HPV) test. The accuracy of the HPV test was previously demonstrated in a 320-patient study that compared Trovagene's test with a competitive test that is based on traditional cervical scraping sample. The study showed Trovagene's test to have analytical sensitivity and specificity of 93 percent and 96 percent, respectively, for detection of high-risk HPV strains, as compared to 78 percent and 86 percent for the competitive test.
For more information visit www.trovagene.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html